TY  - JOUR
AU  - Nikolić, Sandra
AU  - Gazdić-Janković, Marina
AU  - Rosić, Gvozden
AU  - Miletić-Kovačević, Marina
AU  - Jovičić, Nemanja
AU  - Nestorović, Nataša
AU  - Stojković, Petra
AU  - Filipović, Nenad
AU  - Milošević-Đorđević, Olivera
AU  - Selaković, Dragica
AU  - Živanović, Marko
AU  - Seklić, Dragana
AU  - Milivojević, Nevena
AU  - Marković, Aleksandra
AU  - Seist, Richard
AU  - Vasilijić, Sasa
AU  - Stanković, Konstantina M.
AU  - Stojković, Miodrag
AU  - Ljujić, Biljana
PY  - 2022
UR  - http://www.ncbi.nlm.nih.gov/pubmed/35405220
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/4950
AB  - Commercially manufactured or generated through environmental degradation, microplastics (MPs) and nanoplastics (NPs) considerably contribute to environmental pollution. There is a knowledge gap in how exposure to MPs/NPs changes cellular function and affects animal and human health. Here, we demonstrate that after oral uptake, fluorescent polystyrene (PS) nanoparticles pass through the mouse digestive system, accumulate and aggregate in different organs, and induce functional changes in cells and organs. Using cochlear explant as a novel in vitro system, we confirmed the consequences of PS-MP/NP interaction with inner ear cells by detecting aggregates and hetero-aggregates of PS particles in hair cells. The testes of treated males accumulated MPs/NPs in the interstitial compartment surrounding the seminiferous tubules, which was associated with a statistically significant decrease in testosterone levels. Male mice showed increased secretion of interleukins (IL-12p35 and IL-23) by splenocytes while cyto- and genotoxicity tests indicated impaired cell viability and increased DNA damage in spleen tissue. Males also showed a broad range of anxiogenic responses to PS nanoparticles while hippocampal samples from treated females showed an increased expression of Bax and Nlrp3 genes, indicating a pro-apoptotic/proinflammatory effect of PS treatment. Taken together, induced PS effects are also gender-dependent, and therefore, strongly motivate future research to mitigate the deleterious effects of nanosized plastic particles.
PB  - Elsevier Ltd
T2  - Environmental Pollution
T1  - Orally administered fluorescent nanosized polystyrene particles affect cell viability, hormonal and inflammatory profile, and behavior in treated mice.
VL  - 305
DO  - 10.1016/j.envpol.2022.119206
SP  - 119206
ER  - 

@article{
author = "Nikolić, Sandra and Gazdić-Janković, Marina and Rosić, Gvozden and Miletić-Kovačević, Marina and Jovičić, Nemanja and Nestorović, Nataša and Stojković, Petra and Filipović, Nenad and Milošević-Đorđević, Olivera and Selaković, Dragica and Živanović, Marko and Seklić, Dragana and Milivojević, Nevena and Marković, Aleksandra and Seist, Richard and Vasilijić, Sasa and Stanković, Konstantina M. and Stojković, Miodrag and Ljujić, Biljana",
year = "2022",
abstract = "Commercially manufactured or generated through environmental degradation, microplastics (MPs) and nanoplastics (NPs) considerably contribute to environmental pollution. There is a knowledge gap in how exposure to MPs/NPs changes cellular function and affects animal and human health. Here, we demonstrate that after oral uptake, fluorescent polystyrene (PS) nanoparticles pass through the mouse digestive system, accumulate and aggregate in different organs, and induce functional changes in cells and organs. Using cochlear explant as a novel in vitro system, we confirmed the consequences of PS-MP/NP interaction with inner ear cells by detecting aggregates and hetero-aggregates of PS particles in hair cells. The testes of treated males accumulated MPs/NPs in the interstitial compartment surrounding the seminiferous tubules, which was associated with a statistically significant decrease in testosterone levels. Male mice showed increased secretion of interleukins (IL-12p35 and IL-23) by splenocytes while cyto- and genotoxicity tests indicated impaired cell viability and increased DNA damage in spleen tissue. Males also showed a broad range of anxiogenic responses to PS nanoparticles while hippocampal samples from treated females showed an increased expression of Bax and Nlrp3 genes, indicating a pro-apoptotic/proinflammatory effect of PS treatment. Taken together, induced PS effects are also gender-dependent, and therefore, strongly motivate future research to mitigate the deleterious effects of nanosized plastic particles.",
publisher = "Elsevier Ltd",
journal = "Environmental Pollution",
title = "Orally administered fluorescent nanosized polystyrene particles affect cell viability, hormonal and inflammatory profile, and behavior in treated mice.",
volume = "305",
doi = "10.1016/j.envpol.2022.119206",
pages = "119206"
}

Nikolić, S., Gazdić-Janković, M., Rosić, G., Miletić-Kovačević, M., Jovičić, N., Nestorović, N., Stojković, P., Filipović, N., Milošević-Đorđević, O., Selaković, D., Živanović, M., Seklić, D., Milivojević, N., Marković, A., Seist, R., Vasilijić, S., Stanković, K. M., Stojković, M.,& Ljujić, B.. (2022). Orally administered fluorescent nanosized polystyrene particles affect cell viability, hormonal and inflammatory profile, and behavior in treated mice.. in Environmental Pollution
Elsevier Ltd., 305, 119206.
https://doi.org/10.1016/j.envpol.2022.119206

Nikolić S, Gazdić-Janković M, Rosić G, Miletić-Kovačević M, Jovičić N, Nestorović N, Stojković P, Filipović N, Milošević-Đorđević O, Selaković D, Živanović M, Seklić D, Milivojević N, Marković A, Seist R, Vasilijić S, Stanković KM, Stojković M, Ljujić B. Orally administered fluorescent nanosized polystyrene particles affect cell viability, hormonal and inflammatory profile, and behavior in treated mice.. in Environmental Pollution. 2022;305:119206.
doi:10.1016/j.envpol.2022.119206 .

Nikolić, Sandra, Gazdić-Janković, Marina, Rosić, Gvozden, Miletić-Kovačević, Marina, Jovičić, Nemanja, Nestorović, Nataša, Stojković, Petra, Filipović, Nenad, Milošević-Đorđević, Olivera, Selaković, Dragica, Živanović, Marko, Seklić, Dragana, Milivojević, Nevena, Marković, Aleksandra, Seist, Richard, Vasilijić, Sasa, Stanković, Konstantina M., Stojković, Miodrag, Ljujić, Biljana, "Orally administered fluorescent nanosized polystyrene particles affect cell viability, hormonal and inflammatory profile, and behavior in treated mice." in Environmental Pollution, 305 (2022):119206,
https://doi.org/10.1016/j.envpol.2022.119206 . .

TY  - JOUR
AU  - Macut, Đuro
AU  - Mladenović, Violeta
AU  - Bjekić-Macut, Jelica
AU  - Livadas, Sarantis
AU  - Stanojlović, Olivera
AU  - Hrnčić, Dragan
AU  - Rašić-Marković, Aleksandra
AU  - Vojnović-Milutinović, Danijela
AU  - Andrić, Zoran
PY  - 2020
UR  - http://www.eurekaselect.com/172346/article
UR  - http://www.ncbi.nlm.nih.gov/pubmed/31146668
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3969
AB  - Polycystic ovary syndrome (PCOS) is a common endocrine disease in women during reproductive age. It was shown that PCOS women are with high risk for dyslipidemia, glucose intolerance, type 2 diabetes and metabolic syndrome. These factors are considered to represent traditional risk factors for the occurrence of cardiovascular disease. Observed increased risk for hypertension in PCOS women seems to be associated with insulin resistance and hyperinsulinemia. Both conditions interfere with the endothelium-dependent vasodilatation mechanisms causing vascular muscle wall hypertrophy. Obesity and insulin resistance are considered key factors for the alteration of blood pressure in PCOS women. Higher cardiovascular risk is implicated in PCOS with aging and its consequent association with both systolic and diastolic blood pressure. The elements of renin-angiotensin-aldosterone system (RAAS) have an impact on endothelial dysfunction as a marker of cardiovascular damage that could be modified is women with PCOS. Androgens and components of RAAS are involved in the process of atherogenesis in PCOS women. Therefore, it is hypothesized that spironolactone treatment could ameliorate endothelial dysfunction in PCOS women. Recently it was shown that telmisartan, angiotensin II receptor antagonist poses insulinsensitizing capacity to activate PPAR gamma and mediate favorable metabolic and reproductive effects in hypertensive PCOS women.
PB  - Bentham Science Publishers Ltd.
T2  - Current Hypertension Reviews
T1  - Hypertension in Polycystic Ovary Syndrome: Novel Insights.
IS  - 1
VL  - 16
DO  - 10.2174/1573402115666190531071422
SP  - 55
EP  - 60
ER  - 

@article{
author = "Macut, Đuro and Mladenović, Violeta and Bjekić-Macut, Jelica and Livadas, Sarantis and Stanojlović, Olivera and Hrnčić, Dragan and Rašić-Marković, Aleksandra and Vojnović-Milutinović, Danijela and Andrić, Zoran",
year = "2020",
abstract = "Polycystic ovary syndrome (PCOS) is a common endocrine disease in women during reproductive age. It was shown that PCOS women are with high risk for dyslipidemia, glucose intolerance, type 2 diabetes and metabolic syndrome. These factors are considered to represent traditional risk factors for the occurrence of cardiovascular disease. Observed increased risk for hypertension in PCOS women seems to be associated with insulin resistance and hyperinsulinemia. Both conditions interfere with the endothelium-dependent vasodilatation mechanisms causing vascular muscle wall hypertrophy. Obesity and insulin resistance are considered key factors for the alteration of blood pressure in PCOS women. Higher cardiovascular risk is implicated in PCOS with aging and its consequent association with both systolic and diastolic blood pressure. The elements of renin-angiotensin-aldosterone system (RAAS) have an impact on endothelial dysfunction as a marker of cardiovascular damage that could be modified is women with PCOS. Androgens and components of RAAS are involved in the process of atherogenesis in PCOS women. Therefore, it is hypothesized that spironolactone treatment could ameliorate endothelial dysfunction in PCOS women. Recently it was shown that telmisartan, angiotensin II receptor antagonist poses insulinsensitizing capacity to activate PPAR gamma and mediate favorable metabolic and reproductive effects in hypertensive PCOS women.",
publisher = "Bentham Science Publishers Ltd.",
journal = "Current Hypertension Reviews",
title = "Hypertension in Polycystic Ovary Syndrome: Novel Insights.",
number = "1",
volume = "16",
doi = "10.2174/1573402115666190531071422",
pages = "55-60"
}

Macut, Đ., Mladenović, V., Bjekić-Macut, J., Livadas, S., Stanojlović, O., Hrnčić, D., Rašić-Marković, A., Vojnović-Milutinović, D.,& Andrić, Z.. (2020). Hypertension in Polycystic Ovary Syndrome: Novel Insights.. in Current Hypertension Reviews
Bentham Science Publishers Ltd.., 16(1), 55-60.
https://doi.org/10.2174/1573402115666190531071422

Macut Đ, Mladenović V, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, Rašić-Marković A, Vojnović-Milutinović D, Andrić Z. Hypertension in Polycystic Ovary Syndrome: Novel Insights.. in Current Hypertension Reviews. 2020;16(1):55-60.
doi:10.2174/1573402115666190531071422 .

Macut, Đuro, Mladenović, Violeta, Bjekić-Macut, Jelica, Livadas, Sarantis, Stanojlović, Olivera, Hrnčić, Dragan, Rašić-Marković, Aleksandra, Vojnović-Milutinović, Danijela, Andrić, Zoran, "Hypertension in Polycystic Ovary Syndrome: Novel Insights." in Current Hypertension Reviews, 16, no. 1 (2020):55-60,
https://doi.org/10.2174/1573402115666190531071422 . .

TY  - JOUR
AU  - Macut, Đuro
AU  - Bjekić-Macut, Jelica
AU  - Livadas, Sarantis
AU  - Stanojlović, Olivera
AU  - Hrnčić, Dragan
AU  - Rašić-Marković, Aleksandra
AU  - Vojnović-Milutinović, Danijela
AU  - Mladenović, Violeta
AU  - Andrić, Zoran
PY  - 2019
UR  - http://www.eurekaselect.com/169068/article
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3308
AB  - Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women during the reproductive period. True PCOS phenotype is prone to develop metabolic consequences during life. Obese PCOS women with insulin resistance are carrying a risk for developing type 2 diabetes, and influencing liver function by generating liver steatosis and nonalcoholic fatty liver disease (NAFLD). Moreover, serum testosterone of over 3 nmol/L is associated with at least two-fold higher risk for the development of NAFLD in PCOS women. Numerous genes involved in the pathogenesis of hyperandrogenism, insulin resistance and inflammation are associated with the development of NAFLD in PCOS women. Liver biopsy is not considered as the first line procedure for the diagnosis of liver damage in a prevalent condition as PCOS. Therefore, simple and reliable surrogate markers as serum aminotransferases levels or surrogate indexes (i.e. fatty liver index and NAFLD-fatty liver score) could be used for the assessment of fatty liver in PCOS women. First line therapeutic approach for NAFLD in PCOS includes a change in lifestyle that implies dietary regiment and physical activity but without well-defined protocols. Second line therapy considers addition of drugs on the established lifestyle change. Metformin remains the drug of choice for reduction of insulin resistance and liver enzymes level. Liraglutide, glucagon-like peptide-1 receptor agonists, showed favorable effects on the reduction of liver fat content and visceral adipose tissue in overweight women with PCOS. Current review analyzes the impact of metabolic risk factors, diagnostic approach and management options on NAFLD in women with PCOS.
T2  - Current Pharmaceutical Design
T1  - Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome
IS  - 38
VL  - 24
DO  - 10.2174/1381612825666190117100751
SP  - 4593
EP  - 4597
ER  - 

@article{
author = "Macut, Đuro and Bjekić-Macut, Jelica and Livadas, Sarantis and Stanojlović, Olivera and Hrnčić, Dragan and Rašić-Marković, Aleksandra and Vojnović-Milutinović, Danijela and Mladenović, Violeta and Andrić, Zoran",
year = "2019",
abstract = "Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women during the reproductive period. True PCOS phenotype is prone to develop metabolic consequences during life. Obese PCOS women with insulin resistance are carrying a risk for developing type 2 diabetes, and influencing liver function by generating liver steatosis and nonalcoholic fatty liver disease (NAFLD). Moreover, serum testosterone of over 3 nmol/L is associated with at least two-fold higher risk for the development of NAFLD in PCOS women. Numerous genes involved in the pathogenesis of hyperandrogenism, insulin resistance and inflammation are associated with the development of NAFLD in PCOS women. Liver biopsy is not considered as the first line procedure for the diagnosis of liver damage in a prevalent condition as PCOS. Therefore, simple and reliable surrogate markers as serum aminotransferases levels or surrogate indexes (i.e. fatty liver index and NAFLD-fatty liver score) could be used for the assessment of fatty liver in PCOS women. First line therapeutic approach for NAFLD in PCOS includes a change in lifestyle that implies dietary regiment and physical activity but without well-defined protocols. Second line therapy considers addition of drugs on the established lifestyle change. Metformin remains the drug of choice for reduction of insulin resistance and liver enzymes level. Liraglutide, glucagon-like peptide-1 receptor agonists, showed favorable effects on the reduction of liver fat content and visceral adipose tissue in overweight women with PCOS. Current review analyzes the impact of metabolic risk factors, diagnostic approach and management options on NAFLD in women with PCOS.",
journal = "Current Pharmaceutical Design",
title = "Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome",
number = "38",
volume = "24",
doi = "10.2174/1381612825666190117100751",
pages = "4593-4597"
}

Macut, Đ., Bjekić-Macut, J., Livadas, S., Stanojlović, O., Hrnčić, D., Rašić-Marković, A., Vojnović-Milutinović, D., Mladenović, V.,& Andrić, Z.. (2019). Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome. in Current Pharmaceutical Design, 24(38), 4593-4597.
https://doi.org/10.2174/1381612825666190117100751

Macut Đ, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, Rašić-Marković A, Vojnović-Milutinović D, Mladenović V, Andrić Z. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome. in Current Pharmaceutical Design. 2019;24(38):4593-4597.
doi:10.2174/1381612825666190117100751 .

Macut, Đuro, Bjekić-Macut, Jelica, Livadas, Sarantis, Stanojlović, Olivera, Hrnčić, Dragan, Rašić-Marković, Aleksandra, Vojnović-Milutinović, Danijela, Mladenović, Violeta, Andrić, Zoran, "Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome" in Current Pharmaceutical Design, 24, no. 38 (2019):4593-4597,
https://doi.org/10.2174/1381612825666190117100751 . .

TY  - JOUR
AU  - Macut, Đuro
AU  - Vojnović-Milutinović, Danijela
AU  - Rašić-Marković, Aleksandra
AU  - Brkljačić, Jelena
AU  - Bjekić-Macut, Jelica
AU  - Stanojlović, Olivera
PY  - 2018
UR  - http://link.springer.com/10.1007/s42000-018-0073-x
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3220
AB  - Over the last decade, huge achievements have been made in the fields of neurophysiology, molecular endocrinology, and biochemistry, as well as in the successful translation of clinical research into diseases into clinical practice. As regards female reproduction, most of the advances made in this area were achieved in gonadal axis regulation, regulation of behavior through sex steroids, reproductive genetics, preservation of ovarian reproductive function, steroid profiling, and metabolic and overall reproductive outcomes. The coming years are expected to bring further understanding of the relationships between nutrition, energy metabolism, and reproductive function and to succeed in identifying new genetic markers linked to adverse metabolic and unfavorable cardiovascular outcomes in women. From our perspective, future research in the field of female reproduction should be directed toward doing research into genetic reproductive abnormalities and neuroendocrine diseases, pathophysiology, long-term health outcomes for oligo/amenorrhea, hyperandrogenism, and ovulatory dysfunction. It is additionally expected that a better understanding will be gained of the endocrinology of the placenta and of pregnancy, the role of the microbiome in female reproduction, the role of insulin sensitizers, anti-obesity and anti-diabetic drugs, and various advances in the prevention of ovarian damage caused by various oncology therapies, while new therapeutic options for the treatment of infertility, including kisspeptin, will be developed.
T2  - Hormones (Athens, Greece)
T1  - A decade in female reproduction: an endocrine view of the past and into the future.
IS  - 4
VL  - 17
DO  - 10.1007/s42000-018-0073-x
SP  - 497
EP  - 505
ER  - 

@article{
author = "Macut, Đuro and Vojnović-Milutinović, Danijela and Rašić-Marković, Aleksandra and Brkljačić, Jelena and Bjekić-Macut, Jelica and Stanojlović, Olivera",
year = "2018",
abstract = "Over the last decade, huge achievements have been made in the fields of neurophysiology, molecular endocrinology, and biochemistry, as well as in the successful translation of clinical research into diseases into clinical practice. As regards female reproduction, most of the advances made in this area were achieved in gonadal axis regulation, regulation of behavior through sex steroids, reproductive genetics, preservation of ovarian reproductive function, steroid profiling, and metabolic and overall reproductive outcomes. The coming years are expected to bring further understanding of the relationships between nutrition, energy metabolism, and reproductive function and to succeed in identifying new genetic markers linked to adverse metabolic and unfavorable cardiovascular outcomes in women. From our perspective, future research in the field of female reproduction should be directed toward doing research into genetic reproductive abnormalities and neuroendocrine diseases, pathophysiology, long-term health outcomes for oligo/amenorrhea, hyperandrogenism, and ovulatory dysfunction. It is additionally expected that a better understanding will be gained of the endocrinology of the placenta and of pregnancy, the role of the microbiome in female reproduction, the role of insulin sensitizers, anti-obesity and anti-diabetic drugs, and various advances in the prevention of ovarian damage caused by various oncology therapies, while new therapeutic options for the treatment of infertility, including kisspeptin, will be developed.",
journal = "Hormones (Athens, Greece)",
title = "A decade in female reproduction: an endocrine view of the past and into the future.",
number = "4",
volume = "17",
doi = "10.1007/s42000-018-0073-x",
pages = "497-505"
}

Macut, Đ., Vojnović-Milutinović, D., Rašić-Marković, A., Brkljačić, J., Bjekić-Macut, J.,& Stanojlović, O.. (2018). A decade in female reproduction: an endocrine view of the past and into the future.. in Hormones (Athens, Greece), 17(4), 497-505.
https://doi.org/10.1007/s42000-018-0073-x

Macut Đ, Vojnović-Milutinović D, Rašić-Marković A, Brkljačić J, Bjekić-Macut J, Stanojlović O. A decade in female reproduction: an endocrine view of the past and into the future.. in Hormones (Athens, Greece). 2018;17(4):497-505.
doi:10.1007/s42000-018-0073-x .

Macut, Đuro, Vojnović-Milutinović, Danijela, Rašić-Marković, Aleksandra, Brkljačić, Jelena, Bjekić-Macut, Jelica, Stanojlović, Olivera, "A decade in female reproduction: an endocrine view of the past and into the future." in Hormones (Athens, Greece), 17, no. 4 (2018):497-505,
https://doi.org/10.1007/s42000-018-0073-x . .